



The Efficacy of Heat-Clearing (Qingre) and Detoxifying (Jiedu) Traditional Chinese Medicine Gargle for Chemotherapy-Induced Oral Mucositis: A Systematic Review and Meta-Analysis

Zhixian Lin¹*, Jiangfeng Chen² and Sunya Han³

¹Department of Oncology, The Third People's Hospital of Hangzhou, Hangzhou, China, ²Department of Integrated Traditional Chinese and Western Medicine Oncology Ward 1, Hangzhou Cancer Hospital, Hangzhou, China, ³The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China

OPEN ACCESS

Edited by:

Alessandra Durazzo, Council for Agricultural Research and Economics, Italy

Reviewed by:

Jun Xiong, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, China Dongling Zhong, Chengdu University of Traditional Chinese Medicine, China

*Correspondence:

Zhixian Lin 841675972@qq.com

Specialty section:

This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

Received: 09 November 2020 Accepted: 08 February 2021 Published: 29 March 2021

Citation:

Lin Z, Chen J and Han S (2021) The Efficacy of Heat-Clearing (Qingre) and Detoxifying (Jiedu) Traditional Chinese Medicine Gargle for Chemotherapy-Induced Oral Mucositis: A Systematic Review and Meta-Analysis. Front. Pharmacol. 12:627628. doi: 10.3389/fphar.2021.627628 **Objective:** Chemotherapy-induced oral mucositis (CIOM) is an extremely serious complication of cancer. In China, the heat-clearing (Qingre) and detoxifying (Jiedu) traditional Chinese medicine QRJD-TCM gargle has been widely used to treat CIOM. To date, no systematic evaluation has been conducted on the clinical efficacy of QRJD-TCM gargle in treating CIOM. The objective of this systematic review and meta-analysis was to evaluate the efficacy of QRJD-TCM gargle in the treatment of CIOM.

Methods: Relevant randomized controlled trials (RCTs) comparing QRJD-TCM gargle with conventional Western medicine mouthwash (CWMM) for CIOM were confirmed by systematically searching PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese Scientific Journal Database, Wanfang Database, and Sinomed until October 20, 2020. Two researchers independently assessed the risk of bias according to the Cochrane risk-of-bias criteria. Excel 2010 was used in setting up a database of extracted information, and RevMan 5.3.0 was used in analyzing included trial data. The composition of the QRJD-TCM gargle was evaluated.

Results: A total of 25 articles were included in this meta-analysis. Results showed that compared with CWMM, QRJD-TCM gargle can reduce the incidence of CIOM (OR = 0.23, 95% CI [0.18, 0.29], p < 0.00001) and severity of CIOM (grade I–II: OR = 0.36, 95%CI [0.28, 0.46], p < 0.00001; grade III–IV: OR = 0.15, 95%CI [0.09, 0.28], p < 0.00001). In addition, QRJD-TCM gargle improved the effective rate of CIOM (OR = 15.91, 95% CI [7.93, 31.89], p < 0.00001).

1

Abbreviations: CIOM, Chemotherapy-Induced Oral Mucositis; TCM, traditional Chinese medicine; QRJD-TCM, Heat-Clearing (Qingre) and Detoxifying (Jiedu) Traditional Chinese Medicine; CNKI, China National Knowledge Infrastructure; VIP, Chinese Scientific Journal Database; RCTs, randomized controlled trials; CWMM, conventional western medicine mouthwashes; OM, oral mucositis; PRISMA, Systematic Review and Meta-Analysis; OR, odds ratio; CI, confidence interval; I2, I-square.

Conclusion: QRJD-TCM gargle is effective in preventing and treating CIOM. However, more standard, double-blind, and multicenter randomized controlled studies are needed to further confirm the efficacy of QRJD-TCM gargle in the prevention and treatment of CIOM.

Keywords: chemotherapy, oral mucositis, heat-clearing (qingre) and detoxifying (jiedu), traditional Chinese medicine, gargle, meta-analysis

INTRODUCTION

Oral mucositis (OM) is one of the most common adverse reactions caused by chemotherapy; 30–40% of patients receiving normal chemotherapy regimens (excluding high-dose chemotherapy or combined radiotherapy) can develop OM (Lalla et al., 2014; Mahendran et al., 2018). OM is characterized by inflammation, edema, and erythema with or without ulcers (Chaveli-López, 2014; Chaveli-López and Bagán-Sebastián, 2016). Severe OM can lead to difficulty in eating, thereby affecting a patient's nutrition and quality of life. Thus, reducing the doses of chemotherapy drugs or stopping/ postponing chemotherapy may be necessary. These measures ultimately affect the prognoses of cancer patients (Elting et al., 2003; Sonis, 2004).

Owing to the high incidence of chemotherapy-induced oral mucositis (CIOM) in cancer patients and its serious consequences, focusing on the treatment of CIOM is necessary. In clinical practice, CIOM has no standard treatment method, and symptomatic treatment is mainly used. The main methods of prevention and treatment include basic oral care, mouthwash, laser treatment, and cryotherapy (Lalla et al., 2014). Western medicine mouthwashes, which are commonly used in clinical practice and include normal saline, sodium bicarbonate, and chlorhexidine, generally have unstable drug properties and easily cause the imbalance of oropharyngeal flora (McGuire et al., 2013). Laser therapy has the advantages of promoting analgesia and ulcer surface healing, but the aspects of wavelength, power, and duration of treatment remain controversial (Ottaviani et al., 2013; Rezk-Allah et al., 2019). Cryotherapy inhibits the entry of chemotherapy drugs into mucosal tissues and thereby reduces the incidence of CIOM, but it potentially reduces the effectiveness of primary disease treatment; moreover, cold conditions causes psychological resistance (Askarifar et al., 2016; Daugėlaitė et al., 2019). Given the limitations of current treatments, supplementary and/or alternative drugs that alleviate CIOM symptoms are urgently needed.

Chinese herbal medicine has been widely used to treat CIOM (Gesa et al., 2013). According to the theory of traditional Chinese medicine (TCM), chemotherapy drugs belong to the "evil poison" and "drug poison" from the environment. The clinical manifestations of CIOM, including ulcers, redness, swelling, and pain, are the characteristics of TCM heat toxin syndrome. The classic TCM treatment for heat toxin syndrome is heat clearing and detoxifying (Jin et al., 2009; Pan, 2012). In the heat clearing and detoxifying method, a combination of Chinese herbal medicines with clearing heat and/or detoxifying effects is used as the principal drug. Zhou et al. showed that Jiedu Yuyang

decoction with gargle is effective in preventing and treating CIOM, exerts a significant effect on wound healing rate, and promotes swelling and pain relief (Zhou et al., 2019). Another study demonstrated the efficacy and safety of heat clearing (Qingre) and detoxifying (Jiedu) traditional Chinese medicine (QRJD-TCM) gargle in the prevention and treatment of CIOM (Kong, 2020). QRJD-TCM gargle has the advantages of easy availability, low price, and causing few adverse reactions, and does not promote drug resistance. It can not only prevent the occurrence of CIOM but can also effectively control the development of CIOM (Li et al., 2012). However, no systematic review has reported the role of QRJD-TCM gargle in reducing CIOM. To confirm the clinical efficacy of QRJD-TCM gargle in CIOM treatment and provide a reference for clinical practice, we systematically collected studies on QRJD-TCM treatment for CIOM and conducted a systematic review and meta-analysis.

MATERIALS AND METHODS

We conducted this meta-analysis according to the Preferred Reporting Items for the Systematic Review and Meta-Analysis (PRISMA) guidelines. The data were obtained from published trials.

Search Strategy

PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), Wanfang Database, and Sinomed were systematically searched until October 20, 2020. The following search terms were used: "traditional Chinese medicine," "Chinese herbal medicine," "herbs," "heat-clearing," "Qingre," "detoxifying," "Jiedu," "chemotherapy," "oral mucositis," and "oral ulcer." Details of the search strategies are available in **Supplementary Materials 1**. In addition, we reviewed references to eligible studies and related systematic reviews to search relevant articles that may have been missed in the online searches.

Inclusion Criteria

Studies that met all of the following criteria were included:

- 1. Study design was randomized controlled trial (RCT).
- 2. Patients were diagnosed with CIOM according to the China Cancer Symptom Management Practice Guide for Oral Mucositis (Ma et al., 2020), and limitations related to age, ethnicity, gender, cancer type, chemotherapy regimen, or chemotherapy drug dose were nonexistent.

- 3. Patients in the trial group used various kinds of QRJD-TCM gargle. Limitations regarding prescription composition, dosage, or course of treatment were nonexistent.
- 4. Patients in the control group received CWMM. Limitations regarding specific drugs, doses, concentrations, or courses of treatment were nonexistent.
- 5. The studies must include outcome indicators related to CIOM.

Exclusion Criteria

Studies that met any of the following criteria were excluded:

- 1. The full text cannot be retrieved electronically, manually, or by e-mail.
- 2. Nonrandomized controlled trials, such as meta-analysis, retrospective studies, case reports, trial studies, and conference abstracts.
- 3. The patients with OM received radiotherapy or combined chemotherapy.
- 4. The trial group was non-QRJD-TCM intervention.
- 5. The intervention method of the trial group did not adopt the use of a gargle.
- 6. Studies that lack outcome data or cannot be analyzed.

Study Selection and Data Extraction

Three independent reviewers (ZXL, JFC, and SYH) searched and screened the literature according to the research protocol. In the case of discrepancies, the final decision would be made through consensus. We extracted information from the included studies, including general information (first author, country, and year of publication), characteristics of participants (age, gender, sample size, and course of treatment), details of the QRJD-TCM (name of the prescription and composition), and characteristics of the control group and main outcomes.

Risk of Bias Assessment

Two researchers (ZXL and JFC) independently assessed the risk of bias for each trial with the tool of Cochrane Collaboration (Higgins et al., 2011). The bias risk assessment tool contained the following assessment tools: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias. After the risk of bias was assessed, each study was classified as "low risk of bias," "unclear risk of bias," or "high risk of bias" (Higgins and Green, 2008). Any disagreement was settled through consultation with the third researcher.

Data Analysis

The RevMan (Review Manager 5.3) statistical software provided by Cochrane Collaboration was used for data analysis (Cochrane, 2012). Counting data were presented as odds ratio (OR) with a 95% confidence interval (CI). Chi-square test and I-square (I^2 fn2) index were used in testing heterogeneity. When $p \le 0.05$ and $I^2 \ge 50\%$, the random effect model was used. When $p \ge 0.05$ and $l^2 \le 50\%$, the fixed effect model was used. The sources of heterogeneity were analyzed, and the factors that led to heterogeneity were analyzed through subgroup analysis. A p value of ≤ 0.05 was considered statistically significant, and all tests were two-sided tests. In addition, we used funnel plots to assess the existence of publication bias and performed Egger's tests with STATA v16.0. Sensitivity analysis was performed by removing individual studies, and the stability of the results was assessed.

RESULTS

Search Results

A total of 133 articles (the Cochrane Library [n = 8], PubMed [n = 3], embase [n = 1], Sinomed [n = 2], CNKI [n = 42], VIP [n = 8], and Wanfang Data [n = 69]) were retrieved. After we used the EndNote software to delete duplicate articles, we retained 78 studies for further confirmation. Then, by reading the titles and abstracts, 42 articles were excluded because of obvious ineligibility (31 irrelevant studies, one retrospective study, three nonrandomized controlled trials, five reviews, and two case reports). Finally, after reading the full text of the remaining 36 articles, we further removed 11 studies because of at least one of the following reasons: nonclinical studies (n = 1); non-QRJD-TCM (n = 1); intervention method of the trial group did not adopt the use of a gargle (n = 1); participants receiving radiotherapy or combined chemotherapy (n = 2); and lack of data (n = 6). Finally, we included 25 eligible studies for comprehensive analysis. The screening process is shown in Figure 1.

Characteristics of Included Studies

Table 1 summarizes the basic characteristics of the 25 RCTs. One of the studies was conducted in Brazil (Reis et al., 2016), and another one was performed in Turkey (Ezgi et al., 2016). The other studies were carried out in China (23 trials). A total of 2,287 patients were recruited (1,151 in the trial group and 1,136 in the control group), with a sample size of 38 to 180 for a single trial. Patient age ranged from 5 to 83 years. The course of treatment lasted from 5 to 21 days. The control group received CWMM treatment, including normal saline solution (Hang, 2012; Lu and Zhang, 2014; Wang and Hang, 2014; Ezgi et al., 2016; Zhong, 2016), Xilei san (Pan and Yan, 2016; Yan et al., 2016) and cetylpyridinium chloride gargle (Wang et al., 2011; Kong, 2020). The trial group used QRJD-TCM gargle, including Yinhuang gargle (Hang, 2012; Wang and Hang, 2014; Zhong, 2016), and Daihua decoction (Pan and Yan, 2016; Yan et al., 2016). Nineteen studies reported the incidence of CIOM (Wang, 2002; Fang, 2012; Hang, 2012; Zhang, 2012; Duan et al., 2013; He et al., 2013; Xu, 2013; He, 2014; Lu and Zhang, 2014; Wang and Hang, 2014; He, 2015; Ezgi et al., 2016; Reis et al., 2016; Zhong, 2016; Zou et al., 2016; Li, 2018; Cheng, 2019; Zhou et al., 2019; Kong, 2020), 17 studies reported CIOM grade (Wang, 2002; Fang, 2012; Hang, 2012; Zhang, 2012; Duan et al., 2013; He et al., 2013; Xu, 2013; He, 2014; Wang and Hang, 2014; He, 2015; Ezgi et al., 2016; Reis et al., 2016; Zhong, 2016; Zou et al., 2016; Cheng, 2019; Zhou et al., 2019; Kong, 2020), and eight studies reported the effective rate of CIOM



(Jin et al., 2009; Duan et al., 2013; Luo and Yang, 2013; Zhang, 2015; Pan and Yan, 2016; Yan et al., 2016; Wang et al., 2011; Kong, 2020).

Risk of Bias Assessment

Among the 25 included studies, one study used computergenerated random numbers for random allocation (Luo and Yang, 2013), eight studies used random number tables (Wang et al., 2011; Fang, 2012; Duan et al., 2013; Lu and Zhang, 2014; He, 2015; Zhong, 2016; Zou et al., 2016; Zhou et al., 2019), and one study used the lottery method (Reis et al., 2016). The other studies claimed to have used randomization but have not reported details on how to randomize. Such studies were marked as "unclear risk." Apart from two studies (Luo and Yang, 2013; Reis et al., 2016), these studies did not mention the allocation concealment method used. None of the included studies stated whether or not blinding was used but considered that these trials all used objective outcome indicators. Given that the results were not altered by researchers and participants, the studies were identified as "low-risk." In addition, all the RCTs included had no incomplete data and selective reports, so both of them were marked as "low risk". None of the studies had sufficient information that could be used in determining the presence of other significant risks of bias and were thus evaluated as "unclear risk." In general, the overall quality of the methodology included in the study was moderate, and all the risk of bias assessment data are shown in Figure 2.

OUTCOMES MEASURES

Incidence of CIOM

Nineteen studies reported CIOM data at any level during chemotherapy (Wang, 2002; Fang, 2012; Hang, 2012; Li et al., 2012; Zhang, 2012; Duan et al., 2013; He et al., 2013; Xu, 2013; He, 2014; Lu and Zhang, 2014; Wang and Hang, 2014; He, 2015; Ezgi et al., 2016; Reis et al., 2016; Zhong, 2016; Zou et al., 2016; Cheng, 2019; Zhou et al., 2019; Kong, 2020) with a total of 1,690 patients (851 cases in the QRJD-TCM therapy group and 839 cases in the CWMM treatment group). Given that data heterogeneity was not found ($I^2 = 22\%$, p = 0.19), the fixed effect model was used. This finding indicated that the QRJD-TCM gargle therapy group (154/851) was better than the CWMM treatment group (383/839) in reducing the incidence of CIOM (OR = 0.23, 95% CI [0.18, 0.29], p < 0.00001, **Figure 3**).

Grade I–II CIOM

Seventeen studies provided data on grade I–II CIOM (Wang, 2002; Fang, 2012; Hang, 2012; Zhang, 2012; Duan et al., 2013; He et al., 2013; Xu, 2013; He, 2014; Wang and Hang, 2014; He, 2015; Ezgi et al., 2016; Reis et al., 2016; Zhong, 2016; Zou et al., 2016; Cheng, 2019; Zhou et al., 2019; Kong, 2020), with a total of 1,550 patients (781 cases in the QRJD-TCM therapy group and 769 cases in the CWMM treatment group). No significant heterogeneity was found across the studies ($I^2 = 38\%$, p = 0.06) and thus the fixed effect model was used. The results showed that the incidence of grade I–II CIOM

TABLE 1 | Baseline characteristics of included studies.

First	Country	Age/	:	Sex	Sam	ole size	Course of	Intervention measure			Outcome
author (vear)		years	Male	Female	Trial	Control	treatment/ dav	Tri	al group	Control group	
(jour)					group	group	,	Name of the prescription	Composition		
Zhang (2012)	China	26-77	69	57	60	66	15	Compound Scutellaria baicalensis Georgi gargle	Scutellaria baicalensis Georgi [Lamiaceae], Phellodendron chinense C.K.Schneid. [Rutaceae], Mentha canadensis L. [Lamiaceae], Paeonia × suffruticosa Andrews [Paeoniaceae], Corydalis yanhusuo (Y. H. Chou & Chun C.Hsu) W.T.Wang ex Z. Y. Su & C.Y.Wu [Papaveraceae], Carthamus tinctorius L. [Asteraceae], Prunus persica (L.) Batsch [Rosaceae]	Nystatin tablets	1. Incidence of oral mucositis 2. Mucositis severity
Zhou et al. (2019)	China	27–83	48	42	45	45	10	Jiedu Yuyang decoction	Lycium barbarum L. [Solanaceae], Lonicera japonica Thunb. [Caprifoliaceae], Chrysanthemum indicum L. [Asteraceae], Oroxylum indicum (L.) Kurz [Bignoniaceae], Lasiosphaera fenzlii Retch. [Lycoperdaceae], Asarum heterotropoides F.Schmidt [Aristolochiaceae]	Kangfuxin liquid	 Incidence of oral mucositis Mucositis severity
He (2015)	China	18–65	48	32	40	40	21	Jinyu gargle	Lonicera japonica Thunb. [Caprifoliaceae], Mentha canadensis L. [Lamiaceae], Polygonatum odoratum (Mill.) Druce [Asparagaceae], Glycyrrhiza inflata Batalin [Fabaceae]	Gentamicin and 4% sodium bicarbonate solution	 Incidence of oral mucositis Mucositis severity
Cheng (2019)	China	38–81	107	73	90	90	14	Shuanghuang yin	Lonicera japonica Thunb. [Caprifoliaceae], Taraxacum mongolicum HandMazz. [Asteraceae], Lophatherum gracile Brongn. [Poaceae], Blumea balsamifera (L.) DC. [Asteraceae], Mentha	0.9% Sodium chloride solution, Vitamin B12 and Vitamin B2	 Incidence of oral mucositis Mucositis severity
Li (2018)	China	5–14	42	38	40	40	7	Wuji san	Canadensis L. [Lamiaceae] <i>Taraxacum</i> mongolicum HandMazz. [Asteraceae], Glycyrrhiza inflata Batalin [Fabaceae], Bletilla striata (Thunb.) Bchb f. [Orchidaceae]	1% Sodium bicarbonate solution	 Incidence of oral mucositis Mucositis severity
Fang (2012)	China	36–76	38	52	45	45	NP	Solidago decurrens Lour. [Asteraceae] gargle	Solidago decurrens Lour. [Asteraceae]	Gentamicin and normal saline	 Incidence of oral mucositis Mucositis severity
Hang (2012)	China	45-65	68	52	40	40	8	Yinhuang gargle	Lonicera japonica Thunb. [Caprifoliaceae], Scutellaria baicalensis Georgi [Lamiaceae], Coptis chinensis Franch. [Ranunculaceae], Phellodendron chinense C.K.Schneid, [Rutaceae], Scrophularia ningpoensis Hemsl. [Scrophulariaceae], Prunus mume (Siebold) Siebold & Zucc. [Rosaceae], Glycyrrhiza inflata Batalin [Fabaceae], Vigna raciiata (L) B Wilczek	Normal saline	1. Incidence of oral mucositis 2. Mucositis severity

(Continued on following page)

[Fabaceae]

TABLE 1 | (Continued) Baseline characteristics of included studies.

First	Country	Age/		Sex	Sam	ole size	Course of		Intervention measure		Outcome	
author (vear)		years	Male	Female	Trial	Control	treatment/ dav	Т	rial group	Control group		
,					group	group	,	Name of the prescription	Composition			
Zhong (2016)	China	NP	60	40	52	48	8	Yinhuang gargle	Lonicera japonica Thunb. [Caprifoliaceae], Scutellaria baicalensis Georgi [Lamiaceae], Coptis chinensis Franch. [Ranunculaceae], Phellodendron chinense C. K. Schneid. [Rutaceae], Scrophularia ningpoensis Hemsi. [Scrophulariaceae], Prunus mume (Siebold) Siebold & Zucc. [Rosaceae], Glycyrrhiza inflata Batalin [Fabaceae], Vigna radiata (L.) R.Wilczek [Fabaceae]	Normal saline	 Incidence of oral mucositis Mucositis severity 	
Xu (2013)	China	39–73	35	31	36	30	10	Yinxuan decoction	Lonicera japonica Thunb. [Caprifoliaceae], Scrophularia ningpoensis Hemsl. [Scrophulariaceae], Chrysanthemum indicum L. [Asteraceae], Ophiopogon japonicus (Thunb.) Ker Gawl. [Asnaranaceae]	lodine volts and normal saline	 Incidence of oral mucositis Mucositis severity 	
He (2014)	China	43-68	37	39	38	38	NP	No	Scrophularia ningpoensis Hemsi. [Scrophulariaceae], Rehmannia glutinosa (Gaertn.) DC. [Orobanchaceae], Ophiopogon japonicus (Thunb.) Ker Gawl. [Asparagaceae], Lonicera japonica Thunb. [Caprifoliaceae], Isatis tinctoria L. [Brassicaceae] (Banlangen), Sophora tonkinensis Gagnep. [Fabaceae], Coptis chinensis Franch. [Ranunculaceae], Phellodendron chinense C.K.Schneid. [Rutaceae], Astragalus mongholicus Bunge [Fabaceae], Rhus chinensis Mill. [Anacardiaceae], Blumea balsamifera (L.) DC.	0.9% Sodium chloride solution and gentamycin	1. Incidence of oral mucositis 2. Mucositis severity	
Lu and Zhang (2014)	China	39–57	22	38	30	30	10	No	Asteraceaej Lonicera japonica Thunb. [Caprifoliaceae], Forsythia suspensa (Thunb.) Vahl [Oleaceae], Taraxacum mongolicum HandMazz. [Asteraceae], Solidago decurrens Lour. [Asteraceae], Chrysanthemum indicum L. [Asteraceae], Rosa multifora Thunb. [Bosaceae]	Normal saline	 Incidence of oral mucositis Mucositis severity 	
Wang (2002)	China	31–68	62	85	76	71	NP	No	Phellodendron chinense C.K.Schneid. [Rutaceae], Rhus chinensis Mill. [Anacardiaceae], Verbena officinalis L. [Verbenaceae], Senegalia catechu (L.f.) P.J.H.Hurter & Mabb. [Fabaceae], Forsythia suspensa (Thunb.) Vahl [Oleaceae], Blumea balsamifera (L.) DC. [Asteraceae]	Dobell's solution	 Incidence of oral mucositis Mucositis severity 	

(Continued on following page)

TABLE 1 | (Continued) Baseline characteristics of included studies.

First	Country	Age/	:	Sex	Sam	ole size	Course of		Intervention measure		Outcome
author (vear)		years	years Male Female Trial Control		Control	treatment/ dav	Tri	Trial group			
					group	group	,	Name of the prescription	Composition		
He et al. (2013)	China	31–86	34	26	30	30	14	No	Taraxacum mongolicum HandMazz. [Asteraceae], Polygonatum cyrtonema Hua [Asparagaceae], Portulaca oleracea L. [Portulacaceae], Dictamnus dasycarpus Turcz. [Rutaceae], Kochia scoparia (L.) Schrad. [Amaranthaceae], Lonicera japonica Thunb. [Caprifoliaceae]	Metronidazole and sodium chloride injection	 Incidence of oral mucositis Mucositis severity
Zou et al. (2016)	China	5–75	43	37	40	40	14	Compound Scutellaria baicalensis Georgi gargle	Scutellaria baicalensis Georgi [Lamiaceae], Syringa pinnatifolia Hemsl. [Oleaceae], Mentha canadensis L. [Lamiaceae], Panax quinquefolius L. [Araliaceae], Magnolia officinalis Rehder & E.H. Wilson [Magnoliaceae], Prunus persica (L.) Batsch [Rosaceae], Phellodendron chinense C.K.Schneid. [Rutaceae], Corydalis yanhusuo (Y.H.Chou & Chun C.Hsu) W.T.Wang ex Z.Y.Su & C.Y.Wu [Papaveraceae], Paeonia x suffruticosa Andrews [Paeoniaceae]	0.9% normal saline and gentamicin	1. Incidence of oral mucositis 2. Mucositis severity
Wang and Hang (2014)	China	39–71	56	44	50	50	14	Yinhuang gargle	Lonicera japonica Thunb. [Caprifoliaceae], Coptis chinensis Franch. [Ranunculaceae], Scutellaria baicalensis Georgi [Lamiaceae], Phellodendron chinense C.K.Schneid. [Rutaceae], Prunus mume (Siebold) Siebold & Zucc. [Rosaceae], Scrophularia ningpoensis Hemsl. [Scrophulariaceae], Glycyrrhiza inflata Batalin [Fabaceae], Vigna radiata (L.) B.Wilczek [Enbaceae]	Normal saline	1. Incidence of oral mucositis 2. Mucositis severity
Reis et al. (2016)	Brazil	42–79	20	18	20	18	15	Chamomile infusion	A cup of ice chips made with Matricaria chamomilla L. [Asteraceae] at 2.5%	A cup of ice chips made with pure water	 Incidence of oral mucositis Mucositis
Ezgi et al. (2016)	Turkey	18–65	24	36	30	30	5	Sage tea-thyme-peppermint hydrosol oral rinse	Salvia officinalis L. [Lamiaceae], Thymus mongolicus (Ronniger) Ronniger [Lamiaceae], Mentha <i>canadensis</i> L. [Lamiaceae]	Normal saline	1. Incidence of oral mucositis 2. Mucositis
Duan et al. (2013)	China	6–61	69	46	58	57	7	Compound Yinju decoction	Compound Yinju Mixture (produced by the preparation Room of Qingyang Hospital of Traditional Chinese Medicine, NO 20090112)	Chlorhexidine gargle	1. Incidence of oral mucositis 2. Mucositis severity 3. Effective rate
Kong (2020)	China	21–57	38	22	31	31	10	No	Chrysanthemum indicum L. [Asteraceae], Lonicera japonica Thunb. [Caprifoliaceae], Viola philippica Cav. [Violaceae], Bletilla striata (Thunb.) Rchb.f. [Orchidaceae], Mentha <i>canadensis</i> L. [Lamiaceae], Glycyrrhiza inflata Batalin [Fabaceae]	Cetylpyridinium chloride gargle (Continued on fo	 Incidence of oral mucositis Mucositis severity Effective rate

TABLE 1 | (Continued) Baseline characteristics of included studies.

First	Country	Age/	Sex		Sam	ple size	Course of		Intervention measure		Outcome
author (vear)		years	Male	Female	Trial	Control	treatment/	Tri	Control group		
0,					group	group	uuj	Name	Composition		
								of the prescription			
Pan and Yan (2016)	China	20–65	73	47	60	60	10	Daihua decoction	Isatis tinctoria L. [Brassicaceae] (Qingdai), Lonicera japonica Thunb. [Caprifoliaceae], Taraxacum mongolicum HandMazz. [Asteraceae], Angelica dahurica (Hoffm.) Benth. & Hook.f. ex Franch. & Sav. [Apiaceae], Bletilla striata (Thunb.) Rchb.f. [Orchidaceae], Panax notoginseng (Burkill)	Xilei san	Effective rate
									Scutellaria baicalensis Georgi [Lamiaceae], Sepiae		
Yan et al. (2016)	China	20-65	64	36	50	50	10	Daihua decoction	Endoconcha [Sepiidae] Isatis tinctoria L. [Brassicaceae] (Qingdai), Lonicera japonica Thunb. [Caprifoliaceae], Taraxacum mongolicum HandMazz. [Asteraceae], Angelica dahurica (Hoffm.) Benth. & Hook.f. ex Franch. & Sav. [Apiaceae], Bletilla striata (Thunb.) Rchb.f. [Orchidaceae], Panax notoginseng (Burkill) F.H.Chen [Araliaceae], Scutellaria baicalensis Georgi [Lamiaceae], Spiae	Xilei san	Effective rate
Wang et al. (2011)	China	42–83	36	24	30	30	7	Compound Qiju decoction	Endoconcha [seplidae] Lycium barbarum L. [Solanaceae], Lonicera japonica Thunb. [Caprifoliaceae], Oroxylum indicum (L.) Kurz [Bignoniaceae], Chrysanthemum indicum L.	Cetylpyridinium chloride gargle	Effective rate
Zhang (2015)	China	56 ^a	0	101	51	50	7	Qingshengan decoction	Isati aceaej Isatis tinctoria L. [Brassicaceae] (Daqingye), Scrophularia ningpoensis Hemsl. [Scrophulariaceae], Glycyrrhiza infata Bracin, [Esbaceae]	0.02% Furacillin and 1–3% hydrogen peroxide solution	Effective rate
Jin et al. (2009)	China	13–83	33	27	30	28	7	Shuizhongcao decoction	Bubali Cornu [Bovidae], calamitas urinae hominis, Callicarpa macrophylla Vahl Il amiaceae]	Leucovorin and gentamycin	Effective rate
Luo and Yang (2013)	China	57 ^a	92	66	79	79	7	Yinjuhua gargle	Lonicera japonica Thunb. [Caprifoliaceae], Chrysanthemum indicum L. [Asteraceae]	0.02% Furacillin and 1–4% sodium bicarbonate solution	Effective rate

^aMean age.

was significantly lower in the QRJD-TCM therapy group (142/781) than in the CWMM treatment group (281/769) (OR = 0.36, 95% CI [0.28, 0.46], p < 0.00001, **Figure 4**).

Grade III-IV CIOM

Seventeen studies provided data on grade III–IV CIOM (Wang, 2002; Fang, 2012; Hang, 2012; Zhang, 2012; Duan et al., 2013; He et al., 2013; Xu, 2013; He, 2014; Wang and Hang, 2014; He, 2015; Ezgi et al., 2016; Reis et al., 2016; Zhong, 2016; Zou et al., 2016; Cheng, 2019; Zhou et al., 2019; Kong, 2020), with a total of 1,550 patients (781 cases in the QRJD-TCM therapy group and 769 cases

in the CWMM treatment group). No significant heterogeneity was found across the studies (I² = 0%, *p* = 0.94) and thus the fixed effect model was used. The results showed that the incidence of grade III–IV CIOM was significantly lower in the QRJD-TCM therapy group (8/781) than in the CWMM treatment group (70/769) (OR = 0.15, 95% CI [0.09, 0.28], *p* < 0.00001, **Figure 5**).

Effective Rate of CIOM

Eight studies reported effective rates (Jin et al., 2009; Wang et al., 2011; Duan et al., 2013; Luo and Yang, 2013; Zhang, 2015; Pan and Yan, 2016; Yan et al., 2016; Kong, 2020), with a total of 656



	Tria	l l	Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
Cheng et al, 2019	15	90	32	90	8.8%	0.36 [0.18, 0.73]	
Duan et al, 2013	14	58	27	57	6.8%	0.35 [0.16, 0.78]	
Ezgi et al, 2016	9	30	18	30	4.2%	0.29 [0.10, 0.83]	
Fang, 2012	6	45	11	45	3.1%	0.48 [0.16, 1.42]	
Hang et al, 2012	5	40	26	40	7.5%	0.08 [0.02, 0.24]	
He et al, 2013	15	30	20	30	3.3%	0.50 [0.18, 1.42]	+
He et al, 2015	6	40	16	40	4.5%	0.26 [0.09, 0.77]	
He, 2014	4	38	10	38	3.0%	0.33 [0.09, 1.16]	
Kong, 2020	5	31	13	31	3.6%	0.27 [0.08, 0.88]	
Li et al, 2018	1	40	11	40	3.5%	0.07 [0.01, 0.55]	
Lu et al, 2014	3	30	17	30	5.1%	0.08 [0.02, 0.34]	
Paula et al,2016	4	20	7	18	1.9%	0.39 [0.09, 1.67]	
Wang et al, 2014	6	50	32	50	9.3%	0.08 [0.03, 0.21]	
Wang, 2002	8	76	17	71	5.2%	0.37 [0.15, 0.93]	
Xu et al, 2013	6	36	15	30	4.5%	0.20 [0.06, 0.62]	
Zhang, 2012	6	60	18	66	5.1%	0.30 [0.11, 0.81]	
Zhong et al, 2016	7	52	27	48	8.0%	0.12 [0.05, 0.32]	_ .
Zhou et al. 2019	25	45	40	45	5.9%	0.16 [0.05, 0.47]	
Zou et al, 2016	9	40	26	40	6.7%	0.16 [0.06, 0.42]	
Total (95% CI)		851		839	100.0%	0.23 [0.18, 0.29]	•
Total events	154		383				
Heterogeneity: Chi ² = 2	22.93, df =	= 18 (P	= 0.19); l	2 = 22%)		
Test for overall effect:	Z = 12.19	(P < 0.	00001)				Favours [Trial] Favours [control]
3 Forest plats of incid	ence of Cli	\sim M					

	Trial		Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Cheng et al, 2019	13	90	15	90	5.8%	0.84 [0.38, 1.89]	
Duan et al, 2013	14	58	26	57	8.9%	0.38 [0.17, 0.84]	
Ezgi et al, 2016	9	30	18	30	5.7%	0.29 [0.10, 0.83]	
Fang, 2012	5	45	7	45	2.8%	0.68 [0.20, 2.32]	
Hang et al, 2012	5	40	23	40	9.0%	0.11 [0.03, 0.33]	
He et al, 2013	13	30	15	30	3.8%	0.76 [0.28, 2.11]	
He et al, 2015	5	40	13	40	5.1%	0.30 [0.09, 0.93]	
He, 2014	4	38	9	38	3.6%	0.38 [0.11, 1.36]	
Kong, 2020	5	31	7	31	2.6%	0.66 [0.18, 2.36]	
Paula et al,2016	4	20	7	18	2.7%	0.39 [0.09, 1.67]	
Wang et al, 2014	6	50	29	50	11.5%	0.10 [0.04, 0.27]	
Wang, 2002	8	76	12	71	5.0%	0.58 [0.22, 1.51]	
Xu et al, 2013	6	36	12	30	4.9%	0.30 [0.10, 0.94]	
Zhang, 2012	6	60	12	66	4.6%	0.50 [0.17, 1.43]	
Zhong et al, 2016	7	52	24	48	9.7%	0.16 [0.06, 0.41]	
Zhou et al. 2019	24	45	30	45	6.3%	0.57 [0.24, 1.34]	
Zou et al, 2016	8	40	22	40	7.9%	0.20 [0.08, 0.55]	
Total (95% CI)		781		769	100.0%	0.36 [0.28, 0.46]	•
Total events	142		281				
Heterogeneity: Chi ² = 2	5.93, df =	16 (P	= 0.06); l	= 38%			
Test for overall effect: Z	: = 8.27 (F	> < 0.0	0001)				U.UD U.Z I D 20
							Favours [maij Favours [control]



patients (319 cases in the QRJD-TCM therapy group and 337 cases in the CWMM treatment group). Data heterogeneity was not found ($I^2 = 0\%$, p = 0.69), and thus the fixed effect model was applied. The results showed that the clinical effective rate was significantly higher in the QRJD-TCM gargle therapy group (310/319) than the CWMM treatment group (230/337; OR = 15.91, 95% CI [7.93, 31.89], p < 0.00001, **Figure 6**).

In these studies, effective rate subgroup analysis was performed according to different treatment times (7 or 10 days). Five trials (Jin et al., 2009; Wang et al., 2011; Duan et al., 2013; Luo and Yang, 2013; Zhang, 2015) compared the effective rates after 7 days of treatment, and three trials (Pan and Yan, 2016; Yan et al., 2016; Kong, 2020) compared the effective rates after 10 days of treatment. In the 7 and 10 days treatment

	Tria		Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	I M-H, Fixed, 95% Cl
1.1.1 7d							
Duan et al, 2013	13	14	16	27	12.6%	8.94 [1.02, 78.59]	
Jin et al, 2009	28	30	5	28	5.6%	64.40 [11.42, 363.29]	
Luo et al, 2013	77	79	54	79	22.1%	17.82 [4.05, 78.43]	
wang et al, 2011	29	30	22	30	11.9%	10.55 [1.23, 90.66]	
Zhang, 2015	49	51	34	50	21.8%	11.53 [2.49, 53.44]	
Subtotal (95% CI)		204		214	74.0%	16.80 [7.68, 36.73]	•
Total events	196		131				
Heterogeneity: Chi ² = 3	3.06, df = 4	4 (P = (0.55); l ² =	0%			
Test for overall effect:	Z = 7.07 (I	> < 0.0	0001)				
1.1.2 10d							
Kong, 2020	4	5	7	13	12.6%	3.43 [0.30, 39.64]	
Pan et al. 2016	60	60	50	60	6.7%	25.16 [1.44, 439.98]	· · · · · · · · · · · · · · · · · · ·
r arr ot ar, Lo ro				FO	C 70/	100 000 01 10 000 001	
Yan et al, 2016	50	50	42	50	0.1%	20.20 [1.13, 360.28]	
Yan et al, 2016 Subtotal (95% CI)	50	50 115	42	123	26.0%	13.37 [2.99, 59.81]	
Yan et al, 2016 Subtotal (95% CI) Total events	50 114	50 115	42 99	123	26.0%	13.37 [2.99, 59.81]	
Yan et al, 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1	50 114 1.45, df = 1	50 115 2 (P = (42 99).48); I² =	123	26.0%	20.20 [1.13, 360.28] 13.37 [2.99, 59.81]	
Yan et al, 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: 1	50 114 1.45, df = 2 Z = 3.39 (I	50 115 2 (P = (P = 0.0	42 99 0.48); I ² = 007)	123	26.0%	20.20 [1.13, 360.28] 13.37 [2.99, 59.81]	
Yan et al, 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect:	50 114 1.45, df = 2 Z = 3.39 (I	50 115 2 (P = 0 P = 0.0	42 99 0.48); I² = 007)	123 0%	26.0%	20.20 [1.13, 360.28] 13.37 [2.99, 59.81]	
Yan et al, 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI)	50 114 1.45, df = 2 Z = 3.39 (I	50 115 2 (P = 0 P = 0.0 319	42 99 0.48); I² = 007)	123 0% 337	26.0% 100.0%	20.20 [1.13, 360.28] 13.37 [2.99, 59.81] 15.91 [7.93, 31.89]	
Yan et al, 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: Total (95% CI) Total events	50 114 1.45, df = 3 Z = 3.39 (I 310	50 115 2 (P = (P = 0.0 319	42 99 0.48); l² = 007) 230	123 0% 337	6.7% 26.0% 100.0%	20.20 [1.13, 360.28] 13.37 [2.99, 59.81] 15.91 [7.93, 31.89]	•
Yan et al, 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Total events Heterogeneity: Chi ² = 4	50 114 1.45, df = : Z = 3.39 (I 310 4.75, df = 1	50 115 2 (P = (P = 0.0 319 7 (P = (42 99 0.48); l ² = 007) 230 0.69); l ² =	123 0% 337 0%	0.7% 26.0% 100.0%	13.37 [2.99, 59.81]	
Yan et al, 2016 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Total (95% CI) Total events Heterogeneity: Chi ² = 4 Test for overall effect:	50 114 1.45, df = : Z = 3.39 (l 310 4.75, df = 7 Z = 7.80 (l	50 115 2 (P = 0) 319 7 (P = 0) P < 0.0	42 99 0.48); l ² = 007) 230 0.69); l ² = 0001)	123 0% 337 0%	0.7% 26.0%	13.37 [2.99, 59.81]	0.001 0.1 1 10 1000 Eavours [Trial] Eavours [control]

TABLE 2 High-frequency Chinese herbs.

English name	Chinese name	Counts	Frequency (%)
Lonicera japonica Thunb.	Jinyinhua	17	12.8
[Caprifoliaceae]		_	
Chrysanthemum indicum L. [Asteraceae]	Juhua	8	6
Scutellaria baicalensis	Huanggin	7	5.3
Georgi [Lamiaceae]	0.1		
Phellodendron chinense	Huangbo	7	5.3
C.K.Schneid. [Rutaceae]	-		
Taraxacum mongolicum	Pugongying	6	4.5
HandMazz.			
[Asteraceae]			
Mentha canadensis L.	Bohe	6	4.5
[Lamiaceae]			
Scrophularia ningpoensis	Xuanshen	6	4.5
Hemsl.			
[Scrophulariaceae]			
Glycyrrhiza inflata Batalin	Gancao	6	4.5
[Fabaceae]			
Coptis chinensis Franch.	Huanglian	4	3
[Ranunculaceae]			
Bletilla striata (Thunb.)	Baiji	4	3
Rchb.f. [Orchidaceae]			

duration subgroups, meta-analysis results indicated that QRJD-TCM gargle can improve the effective rates of CIOM (7 days: OR = 16.8, 95% CI [7.68, 36.73], p < 0.00001; 10 days: OR = 13.37, 95% CI [2.99, 59.81], p = 0.0007, **Figure 6**).

Effect on Oral Pain

Four trials reported patients' pain scores on a numeric rating scale. Among them, three trials (Wang et al., 2011; Zhang, 2015; Pan and Yan, 2016) reported patient's pain scores before and after



treatment, and one trial (Zhou et al., 2019) reported the grade of pain relief after treatment. Therefore, we were unable to combine the results for meta-analysis. Overall, the pain relief rate of the trial group was better than that of the control group.

High-Frequency Chinese Herbs

The composition of prescriptions of QRJD-TCM gargle included in the 25 studies was statistically analyzed. The Chinese herbs were ranked according to frequency of use, and high-frequency Chinese herbs were selected. The top four Chinese herbs were *Lonicera japonica* Thunb. [Caprifoliaceae] (17, 12.8%), Chrysanthemum indicum L. [Asteraceae] (8, 6%), Scutellaria baicalensis Georgi [Lamiaceae] (7, 5.3%), and Phellodendron chinense C.K.Schneid. [Rutaceae] (7, 5.3%), as shown in **Table 2**.

Adverse Events

Among the 25 studies, one study (He, 2014) reported adverse events, including two cases of nausea and one case of gingival oozing in the trial group and one case of nausea and one case of gingival oozing in the control group, all of which were alleviated after symptomatic treatment. Two studies (Duan et al., 2013; Pan and Yan, 2016) clearly pointed out that no serious adverse events occurred during treatment. No adverse events were mentioned in the remaining studies.

Publication Bias

A funnel plot and Egger's test were used in analyzing publication bias. The funnel plot was drawn using the OR value of each result as the abscissa and SE (log[OR]) as the ordinate. **Figures 7A,E,G** show that the funnel shape was basically inverted and symmetrical. The result of Egger's test was incidence of CIOM: t = -1.73, p = 0.101; grade III–IV CIOM: t = 0.49, p =0.629; effective rate of CIOM: t = -0.55, p = 0.6 (**Figures 7B,F,H**). The results of the two tests showed no obvious publication bias in the studies of incidence of CIOM, grade III–IV CIOM, and effective rate of CIOM. **Figure 7C** shows three studies (Hang, 2012; Wang and Hang, 2014; Cheng, 2019) at the edge of the funnel plot, indicating possible publication bias. The Egger's test result was grade I–II CIOM: t = -0.73, p = 0.476 (**Figure 7D**), indicating that the study of grade I–II CIOM had no obvious publication bias.

Sensitivity Analysis

After we excluded each study, we found no significant change in the results, which all reached statistical significance. This finding indicated that the result data had good stability. After using different analytical models, we found that our conclusions were robust. These analysis results are provided in the supplementary materials (**Supplementary Material 2**).

DISCUSSION

As a disease caused by chemotherapy, CIOM can be alleviated or cured by using TCM gargle (Lockhart and Sonis, 1981). A far as we know, we are the first to conduct a systematic review and meta-analysis for studying the efficacy of QRJD-TCM gargle in preventing and treating CIOM. The analysis of 25 RCTs indicated that the prophylactic QRJD-TCM gargle can significantly reduce the incidence and the grade of CIOM, and therapeutic QRJD-

TCM gargle can considerably increase the cure rate of CIOM. The results of the combined analysis of the incidence of CIOM showed heterogeneity among the studies possibly because of the age of the patients and the different chemotherapy regimens received. Studies have shown that the younger a patient is, the higher the chances that chemotherapy will cause adverse effects on oral health are (Cheng et al., 2011). The type, dosage, and frequency of chemotherapy drugs may have an impact on the occurrence and severity of OM, especially 5fluorouracil, cyclophosphamide, cisplatin, and methotrexate; these chemotherapy drugs are involved in the emergence of changes in the oral mucosa (Ribeiro et al., 2019). The result of the combined analysis of CIOM grade showed that, although the included studies were the same, slight differences in heterogeneity between the two studies were found. Therefore, we speculated that this difference is related to the lack of consistency in the outcome indicator data of grade I-II CIOM. The heterogeneity of the research was less than 50%, indicating that the results of the study were still credible. In addition, the results of the combined analysis of the effective rate of CIOM showed that the clinical effective rate of the trial group was significantly higher than that of the control group. The subgroup analysis compared the cure rate after 7 and 10 days of treatment, and the results were consistent with the results above, suggesting that the course of treatment may have not affected the results of the study. Moreover, only one of the included studies reported adverse events, so QRJD-TCM gargle has been considered safe. Visual assessment of funnel plots and Egger's test results showed no publication bias in any of the above studies. The consistency of these results enhanced the credibility of the conclusion that QRJD-TCM gargle can effectively prevent and treat CIOM. We believe that interventions using QRJD-TCM gargle can be used during the entire course of chemotherapy, that is, QRJD-TCM gargle can be used at the beginning of chemotherapy until the symptoms of OM disappears. This procedure not only can alleviate or even eliminate the symptoms of OM in patients but also ensures the smooth progress of chemotherapy.

According to the interference of chemotherapy on the division and maturation of epithelial cells, the pathogenesis of CIOM can be divided into direct and indirect mechanisms. The direct mechanism is the direct sensitivity of the oral mucosa to apoptosis induced by cytotoxic drug treatment (Lockhart and Sonis, 1981; Verdi, 1993). In the indirect mechanism, some proinflammatory factors that are indirectly toxic to the oral mucosa can promote the occurrence of CIOM, especially those produced by cytotoxic drugs, such as tumor necrosis factor- α (TNF- α), interleukin-1 β (IL-1 β), and interleukin-6 (IL-6) (Oronsky et al., 2018). Sonis (2010) proposed a five-stage model to describe the occurrence and development of CIOM: initiation, up-regulation and generation of messenger signals, signaling and amplification, ulceration, and healing.

Modern studies have proposed that the toxicity of heat clearing and detoxifying methods includes not only exogenous toxins, such as bacteria, viruses, and endotoxins, but also endogenous toxins, such as free radicals and inflammatory cytokines (Lu et al., 2004). Most QRJD-TCM have antiinflammatory activity (Wang et al., 2018). In the included

studies, the most commonly used QRJD-TCM are Lonicera japonica Thunb. [Caprifoliaceae], Chrysanthemum indicum L. [Asteraceae], Scutellaria baicalensis Georgi [Lamiaceae], and Phellodendron chinense C.K.Schneid. [Rutaceae]. Lonicera japonica Thunb. [Caprifoliaceae] has a broad-spectrum antibacterial effect (Zhao, 2007), and its extraction can inhibit LPS-induced NO secretion in RAW264.7 cells, down-regulate the release of IL-1β, IL-6, and TNF-a cytokines, and down-regulate the protein iNOS, COX2, and NF-KB p65 content to exert antiinflammatory effects (Zeng et al., 2020). Chrysanthemum indicum L. [Asteraceae] extraction can inhibit the LPS-induced production of NO, PGE-2, TNF- α , and IL-1 β and the expression of iNOS and COX-2 in macrophages (Cheon et al., 2009). Scutellaria baicalensis Georgi [Lamiaceae] extraction can effectively inhibit the inflammatory response of BV2 cells induced by LPS. Its anti-inflammatory mechanism is to inhibit the Toll-like receptor four inflammatory pathway activated by LPS and reduce the expression of inflammatory factor, such as IL-1 β , IL-6, and TNF- α , thereby alleviating inflammatory response (Yang et al., 2018). The Phellodendron chinense C.K.Schneid. [Rutaceae] ketone contained in Phellodendron chinense C.K.Schneid. [Rutaceae] can reduce the transcription and translation levels of inflammatory factors, such as NO, IL-6, IL-1β, and MCP-1, and significantly inhibit p38-mediated AP-1 signaling by stabilizing the M-RNA of mitogen-activated protein kinase phosphatase-1 (MKP-1), thereby prolonging the expression time of MKP-1 protein (Gao et al., 2018). We found that only the TCM Bletilla striata (Thunb.) Rchb. f. [Orchidaceae] did not have heat clearing and detoxifying effects. Through searching, we found that Bletilla striata (Thunb.) Rchb. f. [Orchidaceae] striata polysaccharide gum in Bletilla striata (Thunb.) Rchb. f. [Orchidaceae] is stable in nature and can significantly promote the DNA synthesis of wound surface cells, improve the ability of cell proliferation, and shorten the healing time of the ulcer surface (Lee et al., 2015; Qiu et al., 2007). At the same time, Bletilla striata (Thunb.) Rchb. f. [Orchidaceae] has a good film-forming property, which can benefit drugs with slow-release effects and has a significant effect on the treatment of oral ulcers (Liu and Jiao, 2015). Therefore, a reasonable combination of these Chinese medicines can theoretically enhance anti-inflammatory effects, improve the oral mucosal environment, and ultimately show a significant prevention and treatment effect on CIOM.

This study has certain limitations. First, the QRJD-TCM gargle is limited to the trials of patients receiving chemotherapy. We excluded trials involving radiotherapy or combined chemotherapy to reduce the heterogeneity between the trials, but we recognized that this procedure limited the external effectiveness and applicability of the study results. Therefore, our results may not be applicable to adult patients receiving radiotherapy or combined chemotherapy. Second, although the QRJD-TCM gargle is a decoction, the specific medicine, dosage, preparation method, and use frequency vary. In addition, no separate analysis of differences in interventions between the

control group was performed. These limitations may require further study. Third, the characteristics of all patients were heterogeneous, which is a significant limitation of our study. Possible confounding factors included patient's age, chemotherapy regimen, frequency, dosage, type of cancer, and combined interventions. Fourth, most of the included studies did not report adverse events, and verifying the safety of the QRJD-TCM gargle for the prevention and treatment of CIOM was difficult. Fifth, most of the included studies were based on China and rarely involved foreign countries. Thus, determining whether the efficacy of QRJD-TCM gargle for CIOM is applicable to different populations around the world was difficult. Sixth, our current study had not been registered, and thus a small level of bias may have been present. However, we still strictly followed the steps of systematic review in the conduct of the meta-analysis. Despite these limitations, the results may be useful to clinicians.

CONCLUSION

The results of this study indicate that QRJD-TCM gargle is more effective than CWMM in the prevention and treatment of CIOM. QRJD-TCM gargle can be used as an alternative or complementary therapy for CWMM in the whole course of chemotherapy. However, owing to the small sample size and poor methodological quality of the included studies, further standard, double-blind, and multicenter randomized controlled studies are needed to confirm the clinical value of QRJD-TCM gargle in the treatment of CIOM. In addition, future studies should focus on how to properly combine Chinese medicines for the preparation of QRJD-TCM gargle that can exert good therapeutic effect against CIOM.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

ZL and JC initiated this study and participated in its design. ZL, JC, and SH performed study selection, data extraction, and data analysis. The manuscript was drafted by ZL and revised by ZL and JC. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.627628/full#supplementary-material.

REFERENCES

- Askarifar, M., Lakdizaji, S., Ramzi, M., Rahmani, A., and Jabbarzadeh, F. (2016). The effects of oral cryotherapy on chemotherapy-induced oral mucositis in patients undergoing autologous transplantation of blood stem cells: a clinical trial. *Iran Red Crescent Med. J.* 18, e24775. doi:10.5812/ircmj.24775
- Chaveli-López, B., and Bagán-Sebastián, J. V. (2016). Treatment of oral mucositis due to chemotherapy. J. Clin. Exp. Dent. 8, e201–9. doi:10.4317/jced.52917
- Chaveli-López, B. (2014). Oral toxicity produced by chemotherapy: a systematic review. J. Clin. Exp. Dent. 6, e81–90. doi:10.4317/jced.51337
- Cheng, J. (2019). Application effect of Shuanghua Yin gargle in treatment of oral mucositis during perichemotherapy period. *Chin. Nurs. Res.* 33, 327–330. doi:10.12102/j.issn.1009-6493.2019.02.034
- Cheng, K. K., Lee, V., Li, C. H., Goggins, W., Thompson, D. R., Yuen, H. L., et al. (2011). Incidence and risk factors of oral mucositis in paediatric and adolescent patients undergoing chemotherapy. *Oral Oncol.* 47, 153–162. doi:10.1016/j. oraloncology.2010.11.019
- Cheon, M. S., Yoon, T., Lee, D. Y., Choi, G., Moon, B. C., Lee, A. Y., et al. (2009). Chrysanthemum indicum Linné extract inhibits the inflammatory response by suppressing NF-kappaB and MAPKs activation in lipopolysaccharide-induced RAW 264.7 macrophages. J. Ethnopharmacol 122, 473–477. doi:10.1016/j.jep. 2009.01.034
- Cochrane (2012). Review manager (RevMan). Copenhagen, CPH: The Cochrane Collaboration.
- Daugėlaitė, G., Užkuraitytė, K., Jagelavičienė, E., and Filipauskas, A. (2019). Prevention and treatment of chemotherapy and radiotherapy induced oral mucositis, *Medicina* 55 (2), 25. doi:10.3390/medicina55020025
- Duan, Y., Li, X. S., Xia, X. J., Kai, J. L., and Yao, J. H. (2013). Compound yinju mixture and gargle in the prevention and treatment of 58 cases of oral ulcer after leukemia chemotherapy. *Trad. Chin. Med. Res.* 26, 23–25. doi:10.3969/j.issn. 1001-6910.2013.03.11
- Elting, L. S., Cooksley, C., Chambers, M., Cantor, S. B., Manzullo, E., and Rubenstein, E. B. (2003). The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. *Cancer* 98, 1531–1539. doi:10.1002/cncr.11671
- Ezgi, M. Y., Nur, I., Leyla, O., Sinem, A. E., and Murat, K. (2016). Sage tea-thyme-peppermint hydrosol oral rinse reduces chemotherapy-induced oral mucositis: a randomized controlled pilot study. *Complement. Ther. Med.* 27, 58–64. doi:10.1016/j.ctim.2016.05.010
- Fang, F. M. (2012). Clinical observation of yizhihuanghua mouthwash liquid to reduce oral ulcer caused by chemotherapy. *Heilongjiang J. Trad. Chin. Med.* 41, 15–16. doi:10.3969/j.issn.1000-9906.2012.06.010
- Gao, Y., Hou, R., Liu, F., Liu, H., Fei, Q., Han, Y., et al. (2018). Obacunone causes sustained expression of MKP-1 thus inactivating p38 MAPK to suppress proinflammatory mediators through intracellular MIF. J. Cell Biochem. 119, 837–849. doi:10.1002/jcb.26248
- Gesa, M. H., Kathrin, B., Janine, R., Thomas, E., Henry, J. G., Matthias, R., et al. (2013). A survey of Chinese medicinal herbal treatment for chemotherapyinduced oral mucositis. *Evid. Based Complement. Alternat Med.*, 2013, 284959. doi:10.1155/2013/284959
- Hang, Y. (2012). Therapeutic observation of silver yellow gargle liquid in the prevention of chemotherapy stomatitis. J. Clin. Med. Pract. 16, 24–25. doi:10. 3969/j.issn.1672-2353.2012.02.010
- He, C. L., Wang, X. M., Dong, C. H., Tian, L. T., Liu, J. J., and Wang, Z. C. (2013). Clinical observation on the prevention and treatment of oral mucositis in patients with chemotherapy. *Inner Mongol J. Trad. Chin. Med.* 32, 6–7. doi:10. 16040/j.cnki.cn15-1101.2013.34.080
- He, N. Y. (2014). Treating 38 cases of stomatitis after chemotherapy with Chinese herbal gargle. *Henan Trad. Chin. Med.* 34, 2233. doi:10.16367/j.issn.1003-5028. 2014.11.108
- He, Y. N. (2015). Effecacy of Jinyu Mouthwash on chemothearphy-caused stomatitis among leukemia patients. J. Nurs. Sci. 30, 39–40. doi:10.3870/ hlxzz.2015.03.039
- Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., et al. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 343, d5928. doi:10.1136/bmj.d5928

- Higgins, J. P., and Green, S. (2008). Cochrane handbook for systematic reviews of interventions. Version 5.0.0. Naunyn-Schmiedebergs Archiv. Exp. Pathol. Pharmakol. 5, S38. doi:10.1002/9780470712184.ch1
- Jin, T., Shen, M. H., Sun, Y. F., and Zhang, J. (2009). Observe the effect of shuizhongcao decoction treating chemotherapy-induced oral ulcer. *Chin. Arch. Trad. Chin. Med.* 27, 303–305. doi:10.13193/j.archtcm.2009.02.80.jint.013
- Kong, S. (2020). Nursing observation on Chinese herbal medicine gargle in the intervention of oral mucositis caused by chemotherapy. *Chin. Med. Mod. Dist. Edu. China* 18, 140–142. doi:10.3969/j.issn.1672-2779.2020.12.057
- Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., et al. (2014). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer* 120, 1453–1461. doi:10.1002/cncr.28592
- Lee, K., Lee, B., Lee, M. H., Kim, B., Chinannai, K. S., Ham, I., et al. (2015). Effect of Ampelopsis Radix on wound healing in scalded rats. *BMC Complement. Altern. Med.* 15, 213. doi:10.1186/s12906-015-0751-z
- Li, M. (2018). Effect of Wujisan on oral ulcer in children with non-Hodgkin's lymphoma treated with methotrexate chemotherapy and its influence on immune status. *Shandong Med. J.* 58, 49–51. doi:10.3969/j.issn.1002-266X. 2018.29.013
- Li, Z. X., Luo, X. Q., and Huang, X. L. (2012). Prevention of bad breath and stomatitis in coma patients by using wild Chrysanthemum solution for oral care. J. Nurs. Sci. 27, 19–20. doi:10.3870/hlxzz.2012.17.019
- Liu, F., and Jiao, Y. N. (2015). Application of Baiji in treating mouth ulcers. *Clin. J. Chin. Med.* 7, 96–97. doi:10.3969/j.issn.1006-6845.2019.19.004
- Lockhart, P. B., and Sonis, S. T. (1981). Alterations in the oral mucosa caused by chemotherapeutic agents. A histologic study. J. Dermatol. Surg. Oncol. 7, 1019–1025. doi:10.1111/j.1524-4725.1981.tb00208.x
- Lu, B., and Zhang, X. Y. (2014). The effect of traditional Chinese medicine gargle in preventing oral mucositis in leukemia patients undergoing chemotherapy. *Shanghai Nurs.* 14, 31–33.
- Lu, F. E., Li, M. Z., and Ye, W. Y. (2004). Study of the therapeutic principle of scavenging evil-heat and removing toxin. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 24, 1124–1129. doi:10.3321/j.issn:1003-5370.2004.12.021
- Luo, W. Y., and Yang, Y. F. (2013). Treatment of 79 cases of oral ulcer after chemotherapy with yinjuhua liquid gargle. *Chin. J. Trad. Med. Sci. Technol.* 20, 207–208. doi:10.3969/j.issn.1005-7072.2013.02.082
- Ma, T. T., Wu, Q., Ouyang, J., Zhang, S. N., Zhang, Y., Xie, J., et al. (2020). Construction of ChineseManagement practice guideline for oral mucositis for cancer patients. *J. Nurses Train.* 35, 1871–1878. doi:10.16821/j.cnki.hsjx.2020.25.028
- Mahendran, V. J., Stringer, A. M., Semple, S. J., Song, Y., and Garg, S. (2018). Advances in the use of anti-inflammatory agents to manage chemotherapyinduced oral and gastrointestinal mucositis. *Curr. Pharm. Des.* 24, 1518–1532. doi:10.2174/1381612824666180409093918
- McGuire, D. B., Fulton, J. S., Park, J., Brown, C. G., Correa, M. E., Eilers, J., et al. (2013). Systematic review of basic oral care for the management of oral mucositis in cancer patients. *Support Care Cancer* 21, 3165–3177. doi:10. 1007/s00520-013-1942-0
- Oronsky, B., Goyal, S., Kim, M. M., Cabrales, P., Lybeck, M., Caroen, S., et al. (2018). A review of clinical radioprotection and chemoprotection for oral mucositis. *Transl Oncol.* 11, 771–778. doi:10.1016/j.tranon.2018.03.014
- Ottaviani, G., Gobbo, M., Sturnega, M., Martinelli, V., Mano, M., Zanconati, F., et al. (2013). Effect of class IV laser therapy on chemotherapy-induced oral mucositis: a clinical and experimental study. *Am. J. Pathol.* 183, 1747–1757. doi:10.1016/j.ajpath.2013.09.003
- Pan, F. F., and Yan, L. H. (2016). Application of Daihua mixture in oral ulcer of chemotherapy patients. J. Qilu Nurs. 22, 108–109. doi:10.3969/j.issn.1006-7256. 2016.15.057
- Pan, H. D. (2012). Clinical observation of Tanreqing injection in the treatment of chemotherapeutic stomatitis. *J. Emerg. Trad. Chin. Med.* 21, 1006–1007. doi:10. 3969/j.issn.1004-745X.2012.06.098
- Qiu, S. L., Wang, X., Li, B., Han, S., and Zhu, H. (2007). Effect on DNA content and cellcycle of wounds by recombinant epiderm al growth factor mixed with *Bletilla striata* (Thunb.) Rchb.f. [Orchidaceae] Striata gelatin. J. Clin. Rehabilitatiretissue Eng. Res. 11, 63–66. doi:10.3321/j.issn:1673-8225.2007. 01.017
- Reis, P. E., Ciol, M. A., Melo NS Figueiredo, P. T., Leite, A. F., and Manzi, N. M. (2016). Chamomile infusion cryotherapy to prevent oral mucositis induced by

chemotherapy: a pilot study. Support Care Cancer 24, 4393–4398. doi:10.1007/s00520-016-3279-y

- Rezk-Allah, S. S., Abd Elshaf, H. M., Farid, R. J., Hassan, M. A. E., and Alsirafy, S. A. (2019). Effect of low-level laser therapy in treatment of chemotherapy induced oral mucositis. *J. Lasers Med. Sci.* 10, 125–130. doi:10.15171/jlms. 2019.20
- Ribeiro, I., de Andrade Lima Neto, E., and Valença, A. M. (2019). Chemotherapy in pediatric oncology patients and the occurrence of oral mucositis. *Int. J. Clin. Pediatr. Dent.* 12, 261–267. doi:10.5005/jp-journals-10005-1633
- Sonis, S. T. (2004). A biological approach to mucositis. J. Support. Oncol. 2, 21-26.
- Sonis, S. T. (2010). New thoughts on the initiation of mucositis. Oral Dis. 16, 597-600. doi:10.1111/j.1601-0825.2010.01681.x
- Verdi, C. J. (1993). Cancer therapy and oral mucositis. An appraisal of drug prophylaxis. Drug Saf. 9, 185–195. doi:10.2165/00002018-199309030-00004
- Wang, C. L., Dai, Z. X., and Dai, X. J. (2011). Effect of mouth gargle with compound goji berry and chrysanthemum soup in patients with oral ulcer. J. Nurs. Sci. 26, 3–5. doi:10.3870/hlxzz.2011.11.003
- Wang, J. Y. (2002). Effect on Chinese herbs decoction gargling to treat and to prevent chemotherapy caused stomatitis. *Chin. Nurs. Res.* 16, 578–579. doi:10. 3969/j.issn.1009-6493.2002.10.011
- Wang, Q., Su, C. P., Zhang, H. M., Ren, Y. L., Wang, W., and Guo, S. Z. (2018). [Anti-inflammatory mechanism of heat-clearing and detoxifying Chinese herbs]. *Zhongguo Zhong Yao Za Zhi* 43, 3787–3794. doi:10.19540/j.cnki. cjcmm.20180611.012
- Wang, Y. L., and Hang, Y. (2014). Observation on the curative effect of Yinhuang Mouthwash in preventing chemotherapeutic stomatitis with deficiency of both Qi and Yin. *Henan Trad. Chin. Med.* B11, 123.
- Xu, P. (2013). Yinxuan Decoction to prevent and treat 36 cases of stomatitis caused by DCF and FOLFOX regimen chemotherapy. *Jilin J. Trad. Chin. Med.* 33, 598–599. doi:10.3969/j.issn.1003-5699.2013.06.028
- Yan, L. H., Liu, X. H., Wang, D. Q., Huang, F., and Shi, X. F. (2016). The clinical observation of Daihua spray for treatment of oral ulcer induced by chemotherapy for patients with gastrointestinal cancer. J. Nurses Train. 31, 395–398. doi:10.16821/j.cnki.hsjx.2016.05.004

- Yang, H., Yang, Y. L., Chen, X., Deng, A. J., Qin, H. L., Wang, Y. H., et al. (2018). Effects and underlying mechanism of extract of Scutellaria baicalensis Georgi against LPS-induced inflammation in BV2 cells Chinese. *Pharm. J.* 53, 268–272. doi:10.11669/cpj.2018.04.005
- Zeng, A. Q., Hua, Y., Chen, C. R., Liu, L., Zhang, M., Luo, Y., et al. (2020). Study on anti-inflammatory pharmacological action of honeysuckle and lonicerae. *China J. Chin. Mater. Med.* 45, 3938–3944. doi:10.19540/j.cnki.cjcmm.20200520.401
- Zhang, H. M. (2015). Qingshengan decoction in treating 51 cases of oral ulcer after chemotherapy. Chin. J. Trad. Med. Sci. Technol. 22, 347–348.
- Zhang, Y. X. (2012). Observation on the effect of compound Huangqin gargle in the prevention and treatment of stomatitis in chemotherapy patients. *Med. J. Chin. People's Health* 24, 1463–1464. doi:10.3969/j.issn.1672-0369.2012.12.036
- Zhao, Y. J. (2007). Study on antimicrobial effects of leaves extracts of Lonicera japonica Thunb. Food Sci. 28, 63–65. doi:10.3321/j.issn:1002-6630.2007.07.009
- Zhong, S. Q. (2016). Study on nursing intervention of Yinhuang gargle in patients with colorectal cancer in chemotherapy induced stomatitis. *Shaanxi J. Trad. Chin. Med.* 37, 302–304. doi:10.3969/j.issn.1000-7369.2016.03.019
- Zhou, X., Dai, Z. X., Deng, L. C., Tao, W. W., and Zhou, Z. X. (2019). Effect of Jiedu Yushang Mouth-washing Recipe in preventing acute leukemia with related oral mucositis. *Shanghai Nurs.* 9, 46–48. doi:10.3969/j.issn.1009-8399.2019.11.012
- Zou, Y. M., Zhang, C. S., and Zhang, L. B. (2016). Prophylaxis of chemotherapyinduced stomatitis by compound gargle of Scutellaria baicalensis Georgi in leukemia. J. Qiqihar Univ. Med. 37, 204–205.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Lin, Chen and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.